KAER Biotherapeutics has announced the launch of the AeroPulsR aerosol device for delivery of high doses of aqueous aerosols in critical care settings. According to KAER, the AeroPulsR can deliver liquids of viscosities up to 50 cP as aerosols with particle sizes in the 2-4 μm range. The device also can deliver aerosols in continuous, periodic, or spontaneous breathing modes at rates up to 3 ml/min.
The company notes that whereas “Current aerosolization techniques are unable to deliver the minimum effective dose necessary to enable positive clinical outcomes – with some products physically degraded by the aerosolization method itself,” AeroPulsR is suitable for high dose delivery of complex molecules, including biologics and oligomers.
Some of the funding for development of the AeroPulsR was provided by grants from the National Institutes of Health, KAER said. The company has previously announced NIH grants for development of its patented aerosol delivery technology for delivery of surfactant to treat acute respiratory distress syndrome (ARDS) and for the treatment of premature infants with Respiratory Distress Syndrome (nRDS). KAER also says that it is “collaborating with leading drug and API manufacturers” on development of human and veterinary applications for the AeroPulsR.
KAER CEO Donovan Yeates commented, “AeroPulsR delivers high concentrations of drugs and minimizes any degradation of the aerosol produced. Furthermore, AeroPulsR replaces the need of integration of an atomizer or mesh nebulizer with a mechanical ventilator.”
Read the KAER Biotherapeutics announcement (on LinkedIn)
